DCT

2:26-cv-08573

Bausch Health Companies Inc v. Sun Pharmaceutical Industries Ltd

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 2:26-cv-08573, D.N.J., 07/10/2026
  • Venue Allegations: Venue is alleged to be proper in the District of New Jersey because Defendant Sun Pharmaceutical Industries, Inc. is incorporated in, maintains a principal place of business in, and has allegedly committed acts of infringement in the district. Venue over Sun Pharmaceutical Industries Ltd. is asserted on the basis that it is a foreign corporation subject to personal jurisdiction.
  • Core Dispute: Plaintiffs allege that Defendants' submission of an Abbreviated New Drug Application (ANDA) to the FDA for approval to market a generic version of Plaintiffs' Relistor® oral tablets constitutes an act of patent infringement.
  • Technical Context: The technology relates to oral pharmaceutical formulations for methylnaltrexone, a peripherally acting opioid antagonist used to treat opioid-induced constipation, a common side effect of chronic pain management.
  • Key Procedural History: This lawsuit was initiated under the Hatch-Waxman Act following Plaintiffs' receipt of a Notice of Paragraph IV Certification from Defendants. In the notice, Defendants assert that the patents-in-suit are invalid, unenforceable, or will not be infringed by their proposed generic product. The asserted patents are listed in the FDA's "Orange Book" for the Relistor® Oral Tablet.

Case Timeline

Date Event
2010-03-11 Priority Date for '276, '651, '461, '417, and '505 Patents
2013-09-03 '276 Patent Issued
2015-02-17 '651 Patent Issued
2016-04-19 '461 Patent Issued
2016-07-19 FDA Approved Relistor® Oral Tablet NDA
2019-06-04 '417 Patent Issued
2019-08-16 '505 Patent Issued
2026-05-26 Plaintiffs Received Defendants' Paragraph IV Notice Letter
2026-07-10 Complaint Filed
2029-09-30 Projected Launch Date for Sun ANDA Product Alleged by Plaintiffs

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,524,276 - "Oral Formulations and Lipophilic Salts of Methylnaltrexone," issued September 3, 2013

The Invention Explained

  • Problem Addressed: The patent addresses the difficulty of creating an effective oral dosage form for methylnaltrexone, a drug used to counteract opioid-induced side effects like constipation '417 Patent, col. 1:19-38 While effective when injected, methylnaltrexone is poorly absorbed when taken orally due to its chemical properties, and previous attempts at oral formulations, including enteric-coated versions, were not consistently effective '417 Patent, col. 3:1-51
  • The Patented Solution: The invention proposes a solid oral formulation that combines methylnaltrexone with an "amphiphilic pharmaceutically acceptable excipient," such as sodium dodecyl sulfate (SLS) '417 Patent, col. 4:47-50 This combination forms an "ion pair," which increases the lipophilicity of the methylnaltrexone molecule, thereby enhancing its absorption in the stomach '417 Patent, col. 4:25-34 The formulation is designed for rapid dissolution, potentially including a fast-acting disintegrant, to produce a combination of a local gastric effect and a systemic effect to induce laxation '417 Patent, col. 4:51-62
  • Technical Importance: This approach provided a method for developing a commercially viable oral tablet for methylnaltrexone, improving patient convenience over injectable forms and addressing a significant unmet need for patients on chronic opioid therapy.

Key Claims at a Glance

  • The complaint alleges infringement of at least one claim without specifying which one Compl. ¶45 Independent claim 1 is representative.
  • The essential elements of independent claim 1 are:
    • A pharmaceutical composition for oral administration;
    • comprising a solid dosage of (i) methylnaltrexone, or a pharmaceutically acceptable salt thereof;
    • and (ii) an amphiphilic pharmaceutically acceptable excipient comprising a saturated or unsaturated, branched or unbranched, cyclic or acyclic C4-30 aliphatic group that is optionally substituted;
    • wherein when the components are in solution, the apparent octanol/water partition coefficient for methylnaltrexone is at least 0.25 at a pH between 1 and 4.
  • The complaint reserves the right to assert other claims, including under the doctrine of equivalents Compl. ¶47

U.S. Patent No. 8,956,651 - "Oral Formulation and Lipophilic Salts of Methylnaltrexone," issued February 17, 2015

The Invention Explained

  • Problem Addressed: As with the '276 Patent, the '651 Patent addresses the challenge of poor oral bioavailability of methylnaltrexone and the inconsistent efficacy of prior oral formulations '417 Patent, col. 1:19-38 '417 Patent, col. 3:1-51
  • The Patented Solution: The invention describes a specific tablet formulation comprising methylnaltrexone and sodium dodecyl sulfate (SDS) as the amphiphilic excipient, where methylnaltrexone is the sole active agent '651 Patent, col. 35:39-49 The patent claims a specific concentration range for the methylnaltrexone and SDS anion components, aiming to optimize the formation of the lipophilic ion pair to enhance absorption and efficacy '651 Patent, col. 35:39-49
  • Technical Importance: The invention provides specific compositional parameters for an effective and reliable oral tablet formulation of methylnaltrexone, moving beyond the general concept to a defined product composition.

Key Claims at a Glance

  • The complaint alleges infringement of at least one claim without specifying which one Compl. ¶57 Independent claim 1 is representative.
  • The essential elements of independent claim 1 are:
    • A pharmaceutical composition for oral administration;
    • comprising a solid dosage of (i) methylnaltrexone, or a pharmaceutically acceptable salt thereof, and (ii) sodium dodecyl sulfate (SDS);
    • wherein the composition is a tablet;
    • wherein methylnaltrexone, or a pharmaceutically acceptable salt thereof, is the sole active agent;
    • and wherein the composition comprises from about 7% to about 75% methylnaltrexone cation and dodecyl sulfate anion, based upon the total weight of the composition.
  • The complaint reserves the right to assert other claims, including under the doctrine of equivalents Compl. ¶59

Multi-Patent Capsules

  • U.S. Patent No. 9,314,461, "Oral Formulations and Lipophilic Salts of Methylnaltrexone," issued April 19, 2016 Compl. ¶31

    • Technology Synopsis: This patent, part of the same family, also addresses the problem of poor oral bioavailability for methylnaltrexone '417 Patent, col. 1:19-38 It claims a specific solid oral tablet composition containing methylnaltrexone and an amphiphilic excipient like SDS, further defined by its dissolution rate-requiring at least 50% to dissolve within 15 minutes in simulated gastric fluid '461 Patent, col. 35:1-8
    • Asserted Claims: At least one unspecified claim Compl. ¶69
    • Accused Features: The entirety of the Sun ANDA Product, alleged to be a bioequivalent generic of Relistor® oral tablets Compl. ¶36 Compl. ¶41

  • U.S. Patent No. 10,307,417, "Oral Formulations and Lipophilic Salts of Methylnaltrexone," issued June 4, 2019 Compl. ¶32

    • Technology Synopsis: This patent also addresses the need for an effective oral formulation of methylnaltrexone '417 Patent, col. 1:19-38 It claims a pharmaceutical composition comprising methylnaltrexone bromide and SDS in a specific weight ratio of about 3:1, further requiring the tablet not to be enterically coated and to meet certain dissolution criteria '417 Patent, col. 36:19-25
    • Asserted Claims: At least one unspecified claim Compl. ¶81
    • Accused Features: The entirety of the Sun ANDA Product Compl. ¶36 Compl. ¶41

  • U.S. Patent No. 10,376,505, "Oral Formulations and Lipophilic Salts of Methylnaltrexone," issued August 16, 2019 Compl. ¶33

    • Technology Synopsis: This patent continues to address the oral bioavailability issue of methylnaltrexone '505 Patent, col. 1:19-38 It claims a specific formulation for oral administration containing methylnaltrexone bromide, SDS, a binder, a chelating agent, and a glidant, among other excipients, forming a complete tablet recipe '505 Patent, col. 37:2-5
    • Asserted Claims: At least one unspecified claim Compl. ¶93
    • Accused Features: The entirety of the Sun ANDA Product Compl. ¶36 Compl. ¶41

III. The Accused Instrumentality

  • Product Identification: The accused instrumentality is the "Sun ANDA Product," which is a proposed generic version of methylnaltrexone bromide in 150 mg oral tablets Compl. ¶2 Compl. ¶36
  • Functionality and Market Context: The complaint alleges that the Sun ANDA Product is intended to be a generic version of Plaintiffs' Relistor® 150mg oral tablet Compl. ¶36 The action was triggered by Sun's filing of an Abbreviated New Drug Application (ANDA) seeking FDA approval to market this product Compl. ¶2 Plaintiffs allege the Sun ANDA Product is "the same, or substantially the same, as Relistor® oral tablets" and that the ANDA contains "bioavailability or bioequivalence data" to support this assertion Compl. ¶40 Compl. ¶41 The technical function of the product is the oral delivery of methylnaltrexone bromide to treat opioid-induced constipation.

No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint does not provide claim charts or a detailed infringement analysis, asserting generally that at least one claim of each patent is infringed by the submission of the Sun ANDA Compl. ¶42 Compl. ¶45 The central theory of infringement is that for the Sun ANDA Product to be approved by the FDA as a generic equivalent of Relistor®, it must be bioequivalent, and to achieve bioequivalence, it must necessarily practice the technology claimed in the Asserted Patents, which are listed in the Orange Book for Relistor® Compl. ¶28 Compl. ¶34 Compl. ¶40 The following tables summarize the likely infringement allegations for a representative independent claim from each of the lead patents.

'276 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A pharmaceutical composition for oral administration comprising a solid dosage of (i) methylnaltrexone, or a pharmaceutically acceptable salt thereof The Sun ANDA Product is described as an oral tablet dosage form containing 150 mg of methylnaltrexone bromide. ¶36 col. 5:1-4
and (ii) an amphiphilic pharmaceutically acceptable excipient comprising a saturated or unsaturated, branched or unbranched, cyclic or acyclic C4-30 aliphatic group that is optionally substituted Plaintiffs' theory of infringement suggests that to achieve bioequivalence with Relistor®, the Sun ANDA Product must contain an excipient that meets this definition. ¶40; ¶41 col. 5:26-47
wherein when the methylnaltrexone... and the... excipient are in solution, the apparent octanol/water partition coefficient for methylnaltrexone is at least 0.25 at a pH between 1 and 4. The complaint alleges the Sun ANDA Product contains bioequivalence data, which Plaintiffs will likely argue proves that Sun's formulation achieves the claimed physicochemical properties to ensure proper absorption. ¶40 col. 6:7-24

'651 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A pharmaceutical composition for oral administration comprising a solid dosage of (i) methylnaltrexone, or a pharmaceutically acceptable salt thereof, and (ii) sodium dodecyl sulfate (SDS) The Sun ANDA Product is alleged to be a generic equivalent of Relistor®; Plaintiffs' theory suggests it must therefore contain methylnaltrexone and an excipient such as SDS to achieve bioequivalence. ¶36; ¶41 col. 35:39-49
wherein the composition is a tablet The Sun ANDA Product is identified as a 150 mg oral tablet. ¶36 col. 35:39-49
wherein methylnaltrexone... is the sole active agent The complaint identifies the Sun ANDA Product only as a generic methylnaltrexone bromide product, implying no other active pharmaceutical ingredients are included. ¶2; ¶36 col. 35:39-49
and wherein the composition comprises from about 7% to about 75% methylnaltrexone cation and dodecyl sulfate anion, based upon the total weight of the composition. To be bioequivalent to Relistor®, which is covered by the patent, Plaintiffs' theory suggests Sun's formulation must fall within the claimed compositional weight percentages. ¶40; ¶41 col. 35:39-49
  • Identified Points of Contention:
    • Scope Questions: A primary point of contention will likely be the scope of the term "amphiphilic pharmaceutically acceptable excipient" in the '276 Patent. The case may turn on whether the specific excipients used in the Sun ANDA Product fall within the construction of this term. A similar question arises for the "sole active agent" limitation in the '651 Patent and whether any other component in Sun's formulation could be construed as an active agent.
    • Technical Questions: The infringement analysis will raise the question of whether the formulation disclosed in Sun's ANDA actually meets the functional limitations of the claims, such as achieving an "apparent octanol/water partition coefficient" of at least 0.25 ('276 Patent) or meeting the specific compositional percentages ('651 Patent). The bioequivalence data in the ANDA will be a key source of evidence for this dispute Compl. ¶40

V. Key Claim Terms for Construction

  • The Term: "amphiphilic pharmaceutically acceptable excipient" (from Claim 1 of the '276 Patent)

    • Context and Importance: This term is the technological core of the invention. The infringement analysis will depend entirely on whether the excipient(s) used in the Sun ANDA Product are found to meet this definition. Practitioners may focus on this term because its breadth is a critical determinant of the patents' scope.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: The specification provides a broad functional definition and numerous examples, stating the excipient may include a "sulfate, sulfonate, nitrate, nitrite, phosphate, or phosphonate moiety" and a "hydrophobic portion" such as a "C4-30 aliphatic chain" '417 Patent, col. 5:29-43 This language may support a broad construction covering any excipient that has both a polar and a non-polar component and can form an ion pair with methylnaltrexone.
      • Evidence for a Narrower Interpretation: The specification places significant emphasis on specific embodiments, particularly dodecyl (lauryl) sulfate '417 Patent, col. 5:51-52 '417 Patent, col. 32:9-41 A defendant may argue that the invention is properly limited to the specific class of excipients disclosed and tested, such as aliphatic sulfates, rather than any compound that could be described as amphiphilic.

  • The Term: "sole active agent" (from Claim 1 of the '651 Patent)

    • Context and Importance: This term is potentially dispositive for infringement. If the Sun ANDA Product contains any other ingredient that could be construed as an "active agent," it would fall outside the literal scope of this claim. Practitioners may focus on this term as a potential non-infringement defense.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: The patent does not define "active agent," leaving it open to its plain and ordinary meaning in the pharmaceutical context, which typically refers to the substance responsible for the drug's primary therapeutic effect. This may support an interpretation that standard excipients, even if they have minor secondary effects, are not "active agents."
      • Evidence for a Narrower Interpretation: The specification does not provide explicit language to narrow this term. However, a defendant could argue that if an excipient in its formulation has a known, independent therapeutic effect (e.g., a laxative effect of its own), it should be considered a second active agent, thereby avoiding infringement of claims with this limitation.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges that Sun will induce and contribute to the infringement of the asserted patents Compl. ¶47 Compl. ¶59 The basis for this allegation in an ANDA case is the filing of an application for a drug whose label will instruct physicians and patients to use it in an infringing manner.
  • Willful Infringement: The complaint does not use the word "willful," but it alleges that "Sun had actual and constructive notice of the Asserted Patents prior to submitting the Sun ANDA" Compl. ¶43 The pleading cites Sun's research and development activities and the FDA's requirements for ANDA submissions as the basis for this pre-suit knowledge Compl. ¶43 These allegations of pre-suit notice form the factual predicate for a potential later claim of willful infringement and a request for enhanced damages.

VII. Analyst's Conclusion: Key Questions for the Case

  • A core issue will be one of definitional scope: can the term "amphiphilic pharmaceutically acceptable excipient", which is central to the asserted patents, be construed broadly to cover the specific formulation components in Sun's ANDA product, or will the court limit the term to the specific embodiments, such as aliphatic sulfates, that are emphasized in the patents' specifications?
  • A second key question will be one of infringement by equivalence: assuming Sun's ANDA product is bioequivalent to Relistor®, does its formulation work in a substantially similar way to achieve a substantially similar result as the claimed invention? The case may turn on whether Sun's formulation achieves bioequivalence by forming a lipophilic ion pair as taught in the patents, or through an alternative, non-infringing mechanism.
  • A third central question for the court will be the validity of the asserted patents, which Sun has challenged in its Paragraph IV certification Compl. ¶38 This will likely focus on whether the claimed combination of methylnaltrexone with a known class of excipients to improve oral absorption would have been obvious to a person of ordinary skill in the art at the time of the invention.
Loading Complaint